MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Bio-Techne
Corporation (NASDAQ:TECH) today announced the release of GMP
ProDots™ Proteins to support cell and gene therapy manufacturing
workflows. GMP ProDots™ Proteins address a critical need to
precisely dose and safely add essential proteins such as growth
factors and cytokines to therapeutic cell cultures. GMP ProDots
Proteins, produced under GMP-grade conditions to meet strict
requirements for human therapies, are neatly packaged lyophilized
spherical 'dots' of protein contained within a sterile bag designed
to be connected to a closed bio-processing culture system.
A critical concern within cell and gene therapy manufacturing is
creating processes that ensure patient safety and robust
therapeutic production. GMP ProDots Proteins address this concern
by allowing for a completely closed system to incorporate critical
cytokines and growth factors for the expansion and growth of
therapeutic cells. The proteins, formulated as lyophilized
spheroids, allow users to visualize the amount of proteins within
each bag, adding a layer of safety to the process. GMP
ProDots products are manufactured with R&D Systems cytokines
and growth factors, widely recognized for superior quality and
reproducibility.
"Sterile addition of growth factors and cytokines to cell
culture is a critical requirement for cell and gene therapy
bio-process production. The GMP ProDots platform achieves this by
enabling sterile growth factor and cytokine addition in a novel
container-closure format while reducing production risk and
operator time," said Sean Kevlahan,
Senior Director of Cell and Gene Therapy.
As the growth in cell therapies continues, the need for
efficient, closed processing steps will grow. GMP ProDots products
are optimized for use with the company's ExCellerate™ Media for
Immune Cell Culture and Cloudz™ Cell Activating Kits to robustly
expand cells for ex vivo cell therapy manufacturing.
The full line of ProDots™ Proteins can be found on the
R&D Systems Website: GMP ProDots™
About Bio-Techne Corporation (NASDAQ: TECH)
Contact:
|
David Clair, Senior
Director, Investor Relations & Corporate Development
|
|
david.clair@bio-techne.com
|
|
612-656-4416
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bio-techne-announces-release-of-gmp-prodots-proteins-to-support-cell-and-gene-therapy-manufacturing-workflows-301071515.html
SOURCE Bio-Techne Corporation